The Technical Analyst
Regen BioPharma, Inc. [RGBP]
Exchange: OTC Sector: Healthcare Industry: Biotechnology
Regen BioPharma, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
15.79% $0.660
America/New_York / 3 mai 2024 @ 15:57
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.72 mill |
| EPS: | -0.240 |
| P/E: | -2.75 |
| Earnings Date: | Jul 22, 2024 |
| SharesOutstanding: | 4.11 mill |
| Avg Daily Volume: | 0.0136 mill |
| RATING 2024-05-03 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.75 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -2.75 | industry: PE 136.10 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.533 - 0.787 ( +/- 19.24%) |
| ATR Model: 14 days |
Forecast:
16:00 - $0.660
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.660
Forecast 2: 16:00 - $0.660
Forecast 3: 16:00 - $0.660
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.660 (15.79% ) |
| Volume | 0.0096 mill |
| Avg. Vol. | 0.0136 mill |
| % of Avg. Vol | 70.15 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RGBP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
RGBP
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is in the early stages of development of its products, and therapies. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-02 09:30:00 - Press Release
Regen Biopharma, Inc. To Discuss Plans To Move Forward With Hemaxellerate Into Clinical Phase 1 At The Emerging Growth Conference On April 4, 2024
Regen biopharma, inc. invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the emerging growth conference. san diego , april 2, 2024 /prnewswire/ -- regen biopharma, inc. (otc pink: rgbp) (otc pink: rgbpp), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, rna vaccines, rna and dna therapeutics and small molecule drugs will be presenting at the emerging growth conference on april 4, 2024 (https://emerginggrowth.com/conference/).
2024-01-08 08:00:00 - Press Release
Regen Biopharma, Inc. To Present At The Emerging Growth Conference On January 10, 2024
Regen biopharma, inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the emerging growth conference. san diego , jan. 8, 2024 /prnewswire/ -- regen biopharma, inc. (otc pink: rgbp) (otc pink: rgbpp), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, rna vaccines, rna and dna therapeutics and small molecule drugs will be presenting at the emerging growth conference on january 10, 2024 (https://emerginggrowth.com/conference/).
2023-11-14 09:00:00 - Press Release
Regen Biopharma, Inc. Ceo Outlines Future Steps In Car T Program
San diego , nov. 14, 2023 /prnewswire/ -- regen biopharma, inc. (otc pink: rgbp) (otc pink: rgbpp) has previously discussed initiation of its duracar car t-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-experiments-validating-its-proprietary-car-t-cell-therapy-301623585.html). this program is designed to create chimeric antigen t-cells that silence the gene for nr2f6.
2023-10-30 09:30:00 - Press Release
Regen Biopharma, Inc. To Discuss Confirmation Study Results On Its Duracar Program At The Emerging Growth Conference On November 1, 2023
Regen biopharma, inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the emerging growth conference. san diego, calif.
2023-10-25 09:30:00 - Press Release
Regen Biopharma, Inc. Receives Second Phase Confirmatory Data On Its Duracar Car-t Cell Therapy Program
Autoimmunity to be targeted san diego , oct. 25, 2023 /prnewswire/ -- regen biopharma, inc. (otc pink: rgbp) (otc pink: rgbpp) has previously discussed initiation of a series of experiments to validate its duracar car t-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-experiments-validating-its-proprietary-car-t-cell-therapy-301623585.html) while also identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs-duracar-indicate-potential-suppression-of-autoimmunity-company-retains-contract-research-organization-to-conduct-additional-confirmatory-studies-301931365...
Latest News
2023-10-30 09:30:00 - PRNewsWire
Regen BioPharma, Inc. to Discuss Confirmation Study Results on Its DuraCar Program at the Emerging Growth Conference on November 1, 2023
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference. SAN DIEGO, Calif.
2023-02-07 14:16:00 - PRNewsWire
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 8, 2023
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference.
2023-01-23 14:46:00 - PRNewsWire
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 25, 2023
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference. SAN DIEGO , Jan. 23, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs, will be presenting at the Emerging Growth Conference on January 25, 2023 (https://emerginggrowth.com/conference/).
2022-11-28 14:49:00 - PRNewsWire
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 30, 2022
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time interactive presentation at the Emerging Growth Conference. SAN DIEGO , Nov. 28, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) (a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs) will be presenting at the Emerging Growth Conference on November 30, 2022 (https://emerginggrowth.com/conference/).